Target the Gene
Silence the Disease

Pipeline

Drug(Disease)
Disease
Pre-clinical
Pre-IND
Phase 1
Phase 2
Phase 3
  • ARO-AAT (Alpha-1 Liver Disease)
    Alpha-1 Liver Disease
    Partnered with Takeda
  • ARO-APOC3 (Hypertriglyceridemia)
    Hypertriglyceridemia
  • ARO-ANG3 (Dyslipidemia)
    Dyslipidemia
  • ARO-HSD (Liver Disease)
    Liver Disease
    Licensed to GlaxoSmithKline
  • ARO-C3 (Complement Mediated Disease)
    Complement Mediated Disease
  • ARO-ENaC2 (Cystic Fibrosis)
    Cystic Fibrosis
  • ARO-MUC5AC (Muco-obstructive)
    Muco-obstructive
  • ARO-RAGE (Muco-obstructive)
    Muco-obstructive
  • ARO-MMP7 (Idiopathic Pulmonary Fibrosis)
    Idiopathic Pulmonary Fibrosis
  • ARO-COV (COVID-19 )
    COVID-19
  • ARO-DUX4 (FSHD)
    FSHD
  • HZN-457 (Gout)
    Gout
    Partnered with Horizon
  • JNJ-3989 (Hepatitis B)
    Hepatitis B
    Licensed to Janssen
  • AMG 890 (Cardiovascular Disease)
    Cardiovascular Disease
    Licensed to Amgen
  • JNJ-75220795 (NASH)
    NASH
    Licensed to Janssen
  • Liver
  • Lung
  • Tumor
  • Muscle

Science

Arrowhead has established a robust and versatile drug discovery and development platform based on proprietary technologies, broad licenses to fundamental intellectual property and extensive scientific expertise after more than a decade working on RNAi-based therapies.

Learn More

About Arrowhead

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes.

 

 

Learn More